Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls
Open Access
- 15 October 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
Abstract
Introduction: Microscopic colitis (MC) is an inflammatory bowel condition with two subtypes, lymphocytic colitis (LC) and collagenous colitis (CC). Unlike patients with ulcerative colitis (UC) and non-inflamed individuals, MC patients have reduced risk of developing colorectal cancer, possibly due to increased immune surveillance in MC patients.Aim: To examine differences in levels of immunomodulatory molecules, including those involved in immune checkpoint mechanisms, in sera from patients with MC and in colonic biopsies from patients with MC and UC compared with controls.Methods: Using Luminex, 23 analytes (4-1BB, 4-1BBL, APRIL, BAFF, BTLA, CD27, CD28, CD80, CTLA-4, E-cadherin, Galectin-3, GITR, HVEM, IDO, IL-2Rα, LAG-3, MICA, MICB, PD-1, PD-L1, PD-L2, sCD40L and TIM-3) were studied in serum from patients with active MC (n = 35) and controls (n = 23), and in colonic biopsies from patients with active LC (n = 9), active CC (n = 16) and MC in histological remission (LC n = 6, CC n = 6), active UC (n = 15) and UC in remission (n = 12) and controls (n = 58).Results: In serum, IDO, PD-1, TIM-3, 4-1BB, CD27, and CD80 were decreased whereas 4-1BBL and IL-2Rα were increased in MC patients compared with controls. In contrast, in biopsies, levels of PD-L2 and 4-1BB were increased in MC and UC patients with active disease. Furthermore, in biopsies from CC and UC but not LC patients with active disease, CTLA-4, PD-1, APRIL, BAFF, and IL-2Rα were increased compared with controls. PD-L1 was increased in CC but not UC or LC patients. CD27 and TIM-3 were decreased in biopsies from MC patients in comparison to controls whereas levels of MICB were decreased in patients with active UC compared with controls.Conclusions: Compared with non-inflamed controls, levels of soluble and membrane-bound immunomodulatory molecules were systemically and locally altered in MC and UC patients, with most analytes being decreased in serum but enhanced in colonic biopsies. These findings contribute to knowledge about checkpoint molecules and their role as biomarkers in MC and may also contribute to knowledge about possible mechanisms behind the seemingly protective effects of MC against colorectal cancer.Keywords
Funding Information
- Region Örebro län (OLL 926161, OLL 960784)
This publication has 63 references indexed in Scilit:
- Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor ImmunityThe Journal of Immunology, 2013
- Mucosal immune environment in colonic carcinogenesis: CD80 up-regulation in colonic dysplasia in ulcerative colitisEuropean Journal of Cancer, 2010
- BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccinationJournal of Clinical Investigation, 2010
- Blocking CD27-CD70 Costimulatory Pathway Suppresses Experimental ColitisThe Journal of Immunology, 2009
- Immune regulation by 4‐1BB and 4‐1BBL: complexities and challengesImmunological Reviews, 2009
- Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel diseaseImmunology Letters, 2005
- Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel diseaseClinical Immunology, 2004
- Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's diseaseClinical Immunology, 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Collagenous colitis: jejunal and colorectal pathology.Journal of Clinical Pathology, 1992